EAEnrique Audain

Enrique Audain

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Enrique Audain has a total of 345 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    hvantk: an agentic multi-omics framework for variant annotation and analysis

    by Enrique Audain, Yasset Perez-Riverol, Marc-Phillip Hitz

    Large-scale genetic variant analysis involves multiple computational steps, data formats, gene and variant annotation sources and compute requirements. Some of the steps like joint calling for large cohorts are run on large compute clusters, while gene/variant classification algorithms can be run in a desktop computer. At the same time, variant annotations such as gene expression and gene constraints metrics from gnomAD are provided in different formats, by resources that frequently change their versions. Here, we present hvantk , a framework that provides a common data model for large-scale annotation and analysis of genetic variants, by extending popular data formats such as Hail MatrixTable and AnnData. hvantk agentically integrates 21 public multi-omic data providers as plugins that a developer, bioinformatician or an AI agent can author without modifying the framework’s core, drives analysis workflows using agent skills, and scales from single desktop computers to high-performance computing clusters. We used hvantk for reanalysing three case-control cohorts, comprising congenital heart disease (CHD), developmental and epileptic encephalopathy (Epi25) and schizophrenia (SCHEMA). Re-ranking of gene-based burden testing results using multi-omic annotations improved the recovery of curated disease genes from 26% to 49% in CHD, 40% to 48% in Epi25 and 51% to 54% in SCHEMA, among the top decile re-ranked genes. Expression at bulk and single-cell levels were the features contributing the most over a baseline of burden, gene constraint and publication count.

  • Open Access

    DNA methylation analysis of NOTCH1 variants reveals the first episignature for non-syndromic congenital heart defects

    by Gregor Dombrowsky, Liselot van der Laan, Ananília Silva, Jeroen Breckpot, Enrique Audain, Anna Wilsdon, Michael A. Levy, Niels Vos, Marcel Mannens, Jiao Wang, et al.

    Background: Congenital heart defects (CHDs) are the most common malformation amongst newborns, with a prevalence of approximately 0.8–2%. The etiology of CHD is highly complex and can be linked to genetic and nongenetic factors. The molecular basis remains partially unclear, and only a minority of patients can be assigned to clear monogenic causes. Methods: Here we analyzed a cohort of 3907 CHD cases and population-matched controls using exome sequencing. In addition, we employed epigenetic profiling on a subset of cases that harbored rare NOTCH1 variants. Results: We identified 24 pathogenic or likely pathogenic single nucleotide variants (SNVs) in NOTCH1 in our exome cohort, as well as a further 15 variants of uncertain significance (VUS) likely to have a deleterious effect. Although the cardiac phenotypes showed some heterogeneity, non-syndromic Tetralogy of Fallot (ToF) and related malformations were the most frequent finding in 56% (22/39). In particular, missense variants altering cysteine residues involved in forming disulfide bridges were identified, specifically in TOF patients. Altogether, NOTCH1 -haploinsufficiency represented the most common monogenic cause in our cohort and accounted for an estimated 1% of CHD cases. Combined with additional cases assembled through collaborations, we present 67 individuals with ultrarare variants affecting NOTCH1 . This prominent role of NOTCH1 calls for an accurate and accessible evaluation of variants. To this end we explored DNA methylation testing and successfully established a NOTCH1 -specific episignature. This signature also displays a robust specificity in relation to 99 other episignatures. Taken together, we found that truncating, splice-altering, as well as missense NOTCH1 variants, can generate a distinct DNAm episignature. Conclusions: We identified that NOTCH1 -haploinsufficiency variants represented the most common monogenic cause in our cohort and accounted for an estimated 1 % of CHD cases. Furthermore, we conclude that methylation profiling can contribute to (NOTCH1) variant interpretation and improve the diagnostic management of CHD patients. Lastly, we established a NOTCH1 -specific episignature, which represents the first non-syndromic signature, significantly extending the scope of patients that can benefit from methylation analysis.


  • Open Access

    ibaqpy: A scalable Python package for baseline quantification in proteomics leveraging SDRF metadata

    by Ping Zheng, Enrique Audain, Henry Webel, Chengxin Dai, Joshua Klein, Marc-Phillip Hitz, Timo Sachsenberg, Mingze Bai, Yasset Perez-Riverol

    Intensity-based absolute quantification (iBAQ) is essential in proteomics as it allows for the assessment of a protein’s absolute abundance in various samples or conditions. However, the computation of these values for increasingly large-scale and high-throughput experiments, such as those using DIA, TMT, or LFQ workflows, poses significant challenges in scalability and reproducibility. Here, we present ibaqpy ( https://github.com/bigbio/ibaqpy ), a Python package designed to compute iBAQ values efficiently for experiments of any scale. ibaqpy leverages the Sample and Data Relationship Format (SDRF) metadata standard to incorporate experimental metadata into the quantification workflow. This allows for automatic normalization and batch correction while accounting for key aspects of the experimental design, such as technical and biological replicates, fractionation strategies, and sample conditions. Designed for large-scale proteomics datasets, ibaqpy can also recompute iBAQ values for existing experiments when an SDRF is available. We showcased ibaqpy’s capabilities by reanalyzing 17 public proteomics datasets from ProteomeXchange, covering HeLa cell lines with 4,921 samples and 5,766 MS runs, quantifying a total of 11,014 proteins. In our reanalysis, ibaqpy is a key component in automating reproducible quantification, reducing manual effort and making quantitative proteomics more accessible while supporting FAIR principles for data reuse.

  • Open Access

    TAK1 operates at the primary cilium in non-canonical TGFB/BMP signaling to control heart development

    by Canan Doganli, Daniel A. Baird, Yeasmeen Ali, Oskar Kaaber Thomsen, Enrique Audain, Line Jessen, Pauline Munck Truelsen, Johanne Bay Mogensen, Maria Schrøder Holm, Kateřina Apolínová, et al.

    Summary: Transforming Growth Factor-Beta-Activated Kinase 1 (TAK1/MAP3K7), along with its upstream regulators TAK1-Binding Protein 2 (TAB2) and the catalytic alpha-subunit of Protein Kinase A (PKA-Cα/PRKACA), has been identified as a pivotal player in regulation of developmental processes. Haploinsufficiency of TAB2 causes Congenital Heart Disease (CHD) and rare variants in PKA-Cα and TAK1 cause cardioacrofacial dysplasia (CAFD), and Frontometaphyseal Dysplasia (FMD) and cardiospondylocarpofacial syndrome (CSCFS), respectively, rare multisystem syndromes, where CHD may appear in the clinical spectrum. We hypothesized that TAK1 plays a significant role in heart development and CHD and addressed this by genetic analysis in CHD patient cohorts and experiments in cell and animal models. Exome sequencing data from 1,471 CHD patients with extracardiac anomalies (syndromic CHD, sCHD), 2,405 patients with nonsyndromic CHD (nsCHD) and 45,082 controls showed increased burden of rare TAB2 and TAK1 variants in sCHD, but not in nsCHD. Detailed characterization of tak1 -/- and tab2 -/- zebrafish mutants revealed cardiac defects (dilated atrium, trabeculation defects, tachycardia and reduced contractility) as well as extracardiac developmental anomalies. RNA sequencing of tak1 -/- mutant hearts showed downregulation of genes encoding core cardiac transcription factors, sarcomeric proteins and extracellular matrix proteins. Experiments with cell cultures and analysis of zebrafish larvae and gastruloids indicated that TAK1 via TAB2 and PKA-Cα is activated at the primary cilium during cardiomyogenesis and that TAK1 activation at this site is enhanced by cardiomyogenic signaling molecules, including ligands of the TGFB/BMP superfamily. Consistent with these findings, CRISPR/Cas9-mediated editing of TAK1 or administration of small molecule inhibitors targeting TAK1 inhibited ciliary signaling and cardiomyocyte differentiation in vitro , while FMD-causing mutations in TAK1 reduced its ciliary localization. In conclusion, our data establishes a central role for TAK1 and its upstream regulators in cardiac development and syndromic CHD, coordinated via the primary cilium.


  • Open Access

    Assessing the contribution of rare variants to congenital heart disease through a large-scale case-control exome study

    by Enrique Audain, Anna Wilsdon, Gregor Dombrowsky, Alejandro Sifrim, Jeroen Breckpot, Yasset Perez-Riverol, Siobhan Loughna, Allan Daly, Pavlos Antoniou, Philipp Hofmann, et al.

    Several studies have demonstrated the value of large-scale human exome and genome data analysis, to maximise gene discovery in rare diseases. Using this approach, we have analysed the exomes of 4,747 cases and 52,881 controls, to identify single genes and digenic interactions which confer a substantial risk of congenital heart disease (CHD). We identified both rare loss-of-function and missense coding variants in ten genes which reached genome-wide significance (Bonferroni adjusted P < 0.05) and an additional four genes with a significant association at a false discovery rate ( FDR) threshold of 5%. We highlight distinct genetic contributions to syndromic and non-syndromic CHD at both single gene and digenic level, by independently analysing probands from these two groups. In addition, by integrative analysis of exome data with single-cell transcriptomics data from human embryonic hearts, we identified cardiac-specific cells as well as putative biological processes underlying the pathogenesis of CHD. In summary, our findings strengthen the association of known CHD genes, and have identified additional novel disease genes and digenic interactions contributing to the aetiology of CHD.


  • Open Access

    A validated heart-specific model for splice-disrupting variants in childhood heart disease

    by Robert Lesurf, Jeroen Breckpot, Jade Bouwmeester, Nour Hanafi, Anjali Jain, Yijing Liang, Tanya Papaz, Jane Lougheed, Tapas Mondal, Mahmoud Alsalehi, et al.

    Congenital heart disease (CHD) is the most common congenital anomaly. Non-canonical splice-disrupting variants are not routinely evaluated by clinical tests. Algorithms including SpliceAI predict such variants, but are not specific to cardiac-expressed genes. Whole genome (WGS) (n=1083) and myocardial RNA-Sequencing (RNA-Seq) (n=114) of CHD cases was used to identify splice-disrupting variants. Using features of variants confirmed to affect splicing in myocardial RNA, we trained a machine learning model that outperformed SpliceAI for predicting cardiac-specific splice-disrupting variants (AUC 0.92 vs 0.66), and was independently validated in 43 cardiomyopathy probands (AUC 0.88 vs 0.64). Application of this model to 971 CHD WGS samples identified 9% patients with splice-disrupting variants in CHD genes. Forty-one% of predicted splice-disrupting variants were deeply intronic. The burden of variants in CHD genes was higher in cases compared with 2,570 controls. Our model improved genetic yield by identifying splice-disrupting variants that are not evaluated by routine tests.

  • Open Access

    Genetics of Congenitally Corrected Transposition of the Great Arteries: next generation sequencing shows a mutation load effect for 156 genes involved in cardiac patterning

    by Yasmine Benadjaoud, Sabina Benko, Fabienne Jabot Hanin, Enrique Audain, Jean François Deleuze, Anne Boland, Christine Bole, Marc Bras, Fanny Bajolle, Morgan Derouk, et al.

    Congenital heart disease (CHD) is a major public health issue. It is considered as a major cause of infant mortality today. We focused on a complex and rare CHD, the congenitally corrected transposition of the great arteries (CCTGA). The aim of this study was to identify the genes that control the alignment of cardiac chambers that are abnormal in CCTGA to further understand the mechanism of this CHD. We analyzed a cohort of 43 CCTGA cases (41 sporadic cases and 2 familial cases) of isolated CCTGA by next generation sequencing analysis (whole-genome sequencing and whole-exome sequencing). Under the hypothesis of Mendelian model including de novo genomic alterations, no major gene effect involved in the disease could be identified. Under the hypothesis of a complex model of inheritance, we highlighted a group of 156 cardiac mutated genes in our patients, in which we found a significant enrichment of rare variants in patients compared to controls in a replication cohort. The highly heterogeneous combinations of susceptibility rare variants, mostly inherited from the healthy mother and father respectively, are correlated with the CCTGA phenotype, any given deleterious variant combination within the CCTGA gene set being specific to the affected individual. Taken together, the cases could be explained by a mutation load of segregated alleles at loci mostly involved in heart tube looping , outflow tract morphogenesis and establishment of left-right asymmetry. Our data suggest that CHD are not Mendelian traits, but rather of polygenic origin. In the majority of cases, both parents harbour a set of susceptibility alleles for the CHD that are inherited by the offspring in a combination that confers the risk of CCTGA.

  • Open Access

    A proteomics sample metadata representation for multiomics integration and big data analysis

    by Chengxin Dai, Anja Füllgrabe, Julianus Pfeuffer, Elizaveta M. Solovyeva, Jingwen Deng, Pablo Moreno, Selvakumar Kamatchinathan, Deepti Jaiswal Kundu, Nancy George, Silvie Fexova, et al.

    The amount of public proteomics data is rapidly increasing but there is no standardized format to describe the sample metadata and their relationship with the dataset files in a way that fully supports their understanding or reanalysis. Here we propose to develop the transcriptomics data format MAGE-TAB into a standard representation for proteomics sample metadata. We implement MAGE-TAB-Proteomics in a crowdsourcing project to manually curate over 200 public datasets. We also describe tools and libraries to validate and submit sample metadata-related information to the PRIDE repository. We expect that these developments will improve the reproducibility and facilitate the reanalysis and integration of public proteomics datasets.


  • Open Access

    Integrative analysis of genomic variants reveals new associations of candidate haploinsufficient genes with congenital heart disease

    by Enrique Audain, Anna Wilsdon, Jeroen Breckpot, Jose M. G. Izarzugaza, Tomas W. Fitzgerald, Anne-Karin Kahlert, Alejandro Sifrim, Florian Wünnemann, Yasset Perez-Riverol, Hashim Abdul-Khaliq, et al.

    Numerous genetic studies have established a role for rare genomic variants in Congenital Heart Disease (CHD) at the copy number variation (CNV) and de novo variant (DNV) level. To identify novel haploinsufficient CHD disease genes, we performed an integrative analysis of CNVs and DNVs identified in probands with CHD including cases with sporadic thoracic aortic aneurysm. We assembled CNV data from 7,958 cases and 14,082 controls and performed a gene-wise analysis of the burden of rare genomic deletions in cases versus controls. In addition, we performed variation rate testing for DNVs identified in 2,489 parent-offspring trios. Our analysis revealed 21 genes which were significantly affected by rare CNVs and/or DNVs in probands. Fourteen of these genes have previously been associated with CHD while the remaining genes (FEZ1, MYO16, ARID1B, NALCN, WAC, KDM5B and WHSC1) have only been associated in small cases series or show new associations with CHD. In addition, a systems level analysis revealed affected protein-protein interaction networks involved in Notch signaling pathway, heart morphogenesis, DNA repair and cilia/centrosome function. Taken together, this approach highlights the importance of re-analyzing existing datasets to strengthen disease association and identify novel disease genes and pathways.


  • Open Access

    A proteomics sample metadata representation for multiomics integration, and big data analysis

    by Chengxin Dai, Anja Füllgrabe, Julianus Pfeuffer, Elizaveta Solovyeva, Jingwen Deng, Pablo Moreno, Selvakumar Kamatchinathan, Deepti Jaiswal Kundu, Nancy George, Silvie Fexova, et al.

    The amount of public proteomics data is increasing at an extraordinary rate. Hundreds of datasets are submitted each month to ProteomeXchange repositories, representing many types of proteomics studies, focusing on different aspects such as quantitative experiments, post-translational modifications, protein-protein interactions, or subcellular localization, among many others. For every proteomics dataset, two levels of data are captured: the dataset description, and the data files (encoded in different file formats). Whereas the dataset description and data file formats are supported by all ProteomeXchange partner repositories, there is no standardized format to properly describe the sample metadata and their relationship with the dataset files in a way that fully allows their understanding or re-analysis. It is left to the user’s choice whether to provide or not an ad hoc document containing this information. Therefore, in many cases, understanding the study design and data requires going back to the associated publication. This can be tedious and may be restricted in the case of non-open access publications. In many cases, this problem limits the generalization and reuse of public proteomics data. Here we present a standard representation for sample metadata tailored to proteomics datasets produced by the HUPO Proteomics Standards Initiative and supported by ProteomeXchange resources. We repurposed the existing data format MAGE-TAB used routinely in the transcriptomics field to represent and annotate proteomics datasets. MAGETAB-Proteomics defines a set of annotation rules that the datasets submitted to ProteomeXchange should follow, ranging from sample properties to data analysis protocols. We also introduce a crowdsourcing project that enabled the manual curation of over 200 public datasets using MAGE-TAB-Proteomics. In addition, we describe an ecosystem of tools and libraries that were developed to validate and submit sample metadata-related information to ProteomeXchange. We expect that these tools will improve the reproducibility of published results and facilitate the reanalysis and integration of public proteomics datasets.